Out of Practice: Why Retirement Doesn’t Always Mean You Stop Seeing Patients
The Importance of Symptom Control: A Holistic Approach to Treating Acromegaly
Pro Golfer Azahara Muñoz Shares Her Experience with Hashimoto’s Disease
Endocrine Society Experts Recommend Individualized Approach to Use of Telehealth
Policy perspective explores factors to maximize effectiveness of telehealth Following rapid growth during the COVID-19 pandemic, telehealth visits are expected to remain an important part of endocrine care, according to a new Endocrine Society policy perspective published in The Journal of Clinical Endocrinology & Metabolism. Health care providers need to consider a variety of...
Positive Clinical Data for Oral Treatment of Acromegaly Presented at ENDO
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
The U.S. Food and Drug Administration (FDA) last month approved a rechargeable neurostimulator and a recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). Medtronic is marketing the products as Intellis™ and Vanta™, respectively. DPN is a debilitating and progressive neurological disorder that affects approximately 30% of people with diabetes,...